pharmaceutical giant johnson johnson agreed buy medical technology firm guidant 254bn Â£13bn
guidant key producer equipment combats heart problems implant defibrillators pacemakers
analysts said deal aimed offsetting johnson johnsons reliance slowing business
pointed mergers likely healthcare industries fragmented pressure cut costs
number johnson johnsons products facing patent expirations company battling fierce competition generic products
meanwhile demand defibrillators give heart small electric shock irregular heartbeat rhythm detected expected increase analysts said
move johnson johnson widely expected firm pay 76 guidant share 6 wednesdays closing price
analysts say us antitrust regulators could force firms shed overlapping stent operations
stents tubes used keep artery open unblocked

